PAI1 Human
Plasminogen Activator Inhibitor-1 Human

Synonyms:
PAI-1, PAI1, PLANH1, SERPINE1, PAIE, PLASMINOGEN ACTIVATOR INHIBITOR, BETA-MIGRATING ENDOTHELIAL-CELL-DERIVED TYPE.

Introduction:
Plasminogen activator inhibitor-1 is the principal inhibitor of tissue plasminogen activator(tPA) and urokinase(uPA), the activators of plasminogenand hence fibrinolysis(the physiological breakdown of blood clots). It is a serine protease inhibitor(serpin) protein (SERPINE1). The other PAI, plasminogen activator inhibitor-2(PAI-2) is secreted by the placentaand only present in significant amounts during pregnancy. In addition, protease nexinacts as an inhibitor of tPA and urokinase. PAI-1, however, is the main inhibitor of the plasminogen activators.

Description:
Constitutively active human plasminogen activator inhibitor 1, stable mutant 14-1B1 having a Molecular mass of 43 kDa. This human form of PAI-1 contains the following four mutations: K154T, Q139L, M354I and N150H. These mutations combine to confer great stability to the otherwise labile molecule essentially locking it into the active conformation.
The PAI1 is purified by proprietary chromatographic techniques.

Physical Appearance:
Sterile Filtered clear colorless solution.

Formulation:
0.05M sodium phosphate 0.15M NaCl and 1mM EDTA
(pH 6.6).

Stability:
Human Plasminogen Activator Inhibitor 1 although stable at 8°C celsius for 1 week, should be stored desiccated below -18°C.

Purity:
Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.

Usage: 
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.